Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4834051 | 0.92 | KDM4E (0.45) | TSHRACHEATMBCHECNR1 | |
| SCHEMBL5256922 | 0.91 | ACHE (0.47) | TSHRACHEKCNH2 | |
| SCHEMBL4845795 | 0.85 | ACHE (0.46) | ACHE | |
| Trifluoroacetic Acid SCHEMBL4838222 | 0.84 | ACHE (0.41) | ACHEKCNH2 | |
| SCHEMBL5255347 | 0.84 | ALDH1A1 (0.51) | — | |
| SCHEMBL4835015 | 0.82 | ACHE (0.44) | ACHE | |
| SCHEMBL4842140 | 0.82 | CHEK2 (0.53) | ACHE | |
| SCHEMBL6221605 | 0.82 | CYP4F2 (0.40) | ACHEATMBCHECNR1CNR2 | |
| SCHEMBL2973958 | 0.81 | ACHE (0.60) | ACHEMCHR1 | |
| SCHEMBL6221325 | 0.81 | CSF1R (0.41) | TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TSHR 1384/4885ACHE 1390/4885ATM 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.